SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC)
CTIC 9.0900.0%Jun 26 5:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Extra Pale who wrote (377)1/21/2005 9:41:25 AM
From: Icebrg  Read Replies (1) of 946
 
"well-entrenched bias against the co by investors"

There are a number of reasons that go back a couple of years. Most of them date back to a time before I became interested in the company, so my picture is somewhat blurred.

There was a poorly designed phase III trial that failed badly.

The CEO has the service of a corporate jet, while the company is starved for money.

The CEO was borrowing money from the company (while this was still allowed). It has been repaid by now btw.

The CEO has a habit of promising too much. Of course, most of them do, but still.

There was a funny story about a botched PR, which I never quite got to grips with. But the idea was evidently that there was a lot of scepticism within the company at the time with regard to Xyotax.

The CEO did last year indicate that a partnership with big pharma was forthcoming. It didn't. Instead they went ahead and merged with NovusPharma which in my opinion was a better move, but still.

The CEO has been very forthcoming with Stellar 3 survival data in a way that I have never seen before. Many might feel that this is over the top.

There is a huge short position. Which makes investors careful.

Agree fully about the Yahoo board. It is first class.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext